Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
26141201
DOI
10.1016/j.amjcard.2015.05.022
PII: S0002-9149(15)01346-6
Knihovny.cz E-resources
- MeSH
- Adrenergic beta-Antagonists therapeutic use MeSH
- Adult MeSH
- Cardiomyopathy, Hypertrophic complications drug therapy MeSH
- Phosphodiesterase 5 Inhibitors therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- Prevalence MeSH
- Retrospective Studies MeSH
- Risk Factors MeSH
- Aged MeSH
- Sexual Dysfunction, Physiological drug therapy epidemiology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adrenergic beta-Antagonists MeSH
- Phosphodiesterase 5 Inhibitors MeSH
The prevalence of sexual dysfunction (SD) in men with hypertrophic cardiomyopathy (HC) remains unknown, yet its clinical relevance may be high given that its treatment-phosphodiesterase 5 inhibitors (PDE5i)-can increase the left ventricular outflow tract pressure gradient. In this retrospective study, we evaluated the medical records of consecutively seen men with HC for the evidence of SD (defined as SD diagnosis noted in the medical record, the use of medications unique for SD, or SD reported by the patient on a routine clinical questionnaire). Of the 283 consecutively seen men with HC (mean age 52.9 ± 14.1 years), 63 patients (22%) with SD were identified. Of those with SD, 38% were recorded as regularly using PDE5i. In conclusion, SD and the use of PDE5i present a relatively common occurrence in men with HC, and further studies are needed to develop an evidence-guided algorithm for safe implementation of SD therapies in this most common inherited cardiomyopathy.
References provided by Crossref.org
Increased heart rate with sleep disordered breathing in hypertrophic cardiomyopathy
